Venus Remedies has received approval from the Government of India under PLI 2.0 of the Production Linked Incentive (PLI) Scheme for manufacturers of pharmaceutical goods registered in India. Venus is one of the 10 non-MSME pharmaceutical companies under category-C which have been granted approval under the PLI Scheme. As per the scheme, the Company will be eligible for incentive for the financial years 2022-23 to 2027-28, subject to fulfillment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers. It has world-class manufacturing facilities in Panchkula and Baddi (in India) and Werne (in Germany) and research and development center in Venus Medicine Research Centre (in India).
